MCRB Seres Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%
Returns
ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $789,000 | $0 |
| R&D expense | $49.06M | $64.60M |
| SG&A expense | $39.16M | $53.18M |
| Operating income | -$93.97M | -$121.31M |
| Interest expense | $0 | $0 |
| Income tax | $0 | $0 |
| Net income | $5.70M | $136,000 |
| EBITDA | -$89.84M | -$115.85M |
| EPS (basic) | 0.64 | 0.00 |
| EPS (diluted) | 0.64 | 0.00 |
| Weighted avg. shares (diluted) | 8.87M | 7.77M |
| Balance sheet | ||
| Cash & equivalents | $45.77M | $39.46M |
| Receivables | $157,000 | $0 |
| Current assets | $49.38M | $38.67M |
| PP&E, net | $7.63M | $11.53M |
| Total assets | $138.19M | $139.81M |
| Current liabilities | $19.32M | $41.22M |
| Total liabilities | $93.97M | $126.03M |
| Shareholders' equity | $44.22M | $13.78M |
| Shares outstanding | 9.56M | 8.65M |
| Cash flow statement | ||
| Operating cash flow | $1.12M | -$148.61M |
| Capital expenditure | $252,000 | $380,000 |
| Free cash flow | $865,000 | -$148.99M |
| Investing cash flow | -$42,000 | $142.29M |
| Financing cash flow | $13.90M | -$90.37M |
| Depreciation & amortization | $4.13M | $5.47M |
| Stock-based compensation | $10.84M | $20.97M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.